Histamine plus IL-2 for early pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding histamine and a medicine called interleukin-2 (IL-2) can help people with newly diagnosed, operable pancreatic cancer. Participants will need to meet cancer and health criteria, including heart safety and pregnancy prevention rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign a consent form before starting treatment
- You are an adult age 18 or older
- A surgeon says you are healthy enough for pancreatic surgery
- Your pancreatic cancer diagnosis was confirmed by scans and/or a tissue test (cytology)
- You do not have serious, unstable heart problems or recent major heart events
- If you could become pregnant, you can use effective birth control during the study and for 5 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial studies a new treatment called XH001 combined with standard immunotherapy and chemotherapy for people whose pancreatic cancer has been surgically removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of two medications (HRS-4642 and AG) given before and after surgery for pancreatic cancer that can be removed. The goal is to see if this treatment helps prevent the cancer from coming back.
This trial tests a combination of an oncolytic virus (a virus that targets cancer cells), an immunotherapy drug (anti-PD1), and chemotherapy given before surgery for people with borderline resectable or locally advanced pancreatic cancer. The goal is to see if this approach can shrink the tumor enough to make surgery more successful.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.